Investors Offered Lead Role in Aardvark Therapeutics Securities Fraud Lawsuit

Rosen Law Firm has initiated legal proceedings against Aardvark Therapeutics, Inc. (NASDAQ: AARD). The firm is calling on purchasers of the company's common stock pursuant to or traceable to its registration statement and prospectus to participate.

The lawsuit alleges that Aardvark Therapeutics made false or misleading statements or failed to disclose material information in its registration statement and prospectus related to its initial public offering. These alleged misrepresentations may have caused financial harm to investors.

Rosen Law Firm is urging investors who acquired Aardvark Therapeutics shares during the specified period and suffered losses to contact the firm. The firm's attorneys will assess the merits of the legal claims and guide investors through the process of seeking recovery.

The class-action lawsuit seeks to recover damages for investors who were allegedly harmed by the company's disclosures surrounding its public offering. Further details are available through the law firm.